LA JOLLA PHARMACEUTICAL CO Form 425 March 01, 2010

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

# FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

# La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

0-24274

(Commission

File Number)

Delaware

(State or other jurisdiction of incorporation)

4365 Executive Drive, Suite 300, San Diego, California

(Address of principal executive offices)

Registrant s telephone number, including area code:

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[x] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

33-0361285

(I.R.S. Employer Identification No.)

92121

(Zip Code)

(858) 452-6600

March 1, 2010

#### Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 425

#### <u>Top of the Form</u> Item 8.01 Other Events.

On March 1, 2010, La Jolla Pharmaceutical Company issued a press release providing details concerning the adjournment of its special meeting of stockholders initially held on February 26, 2010. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. 99.1 Press Release Dated March 1, 2010.

### Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 425

#### Top of the Form

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

March 1, 2010

By: /s/ Gail A. Sloan

Name: Gail A. Sloan Title: Vice President of Finance and Secretary

## Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 425

#### Top of the Form

Exhibit Index

Exhibit No.	Description

99.1

Press Release Dated March 1, 2010.